Pioneer Investment Management Inc. boosted its stake in shares of TESARO, Inc. (NASDAQ:TSRO) by 195.6% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 317,753 shares of the biopharmaceutical company’s stock after buying an additional 210,273 shares during the period. Pioneer Investment Management Inc. owned approximately 0.59% of TESARO worth $44,441,000 at the end of the most recent reporting period.
Several other hedge funds have also recently made changes to their positions in TSRO. Pictet Asset Management Ltd. raised its stake in shares of TESARO by 39.4% in the second quarter. Pictet Asset Management Ltd. now owns 399,105 shares of the biopharmaceutical company’s stock valued at $59,590,000 after buying an additional 112,869 shares during the period. IFP Advisors Inc raised its stake in shares of TESARO by 6.3% in the second quarter. IFP Advisors Inc now owns 4,471 shares of the biopharmaceutical company’s stock valued at $625,000 after buying an additional 265 shares during the period. Candriam Luxembourg S.C.A. raised its stake in shares of TESARO by 51.5% in the second quarter. Candriam Luxembourg S.C.A. now owns 162,060 shares of the biopharmaceutical company’s stock valued at $22,667,000 after buying an additional 55,060 shares during the period. World Asset Management Inc purchased a new stake in shares of TESARO during the second quarter valued at $227,000. Finally, Daiwa Securities Group Inc. raised its stake in shares of TESARO by 4.2% in the second quarter. Daiwa Securities Group Inc. now owns 19,125 shares of the biopharmaceutical company’s stock valued at $2,675,000 after buying an additional 764 shares during the period.
Shares of TESARO, Inc. (NASDAQ:TSRO) traded up 4.41% on Friday, reaching $113.86. The company’s stock had a trading volume of 1,643,726 shares. The company’s market cap is $6.17 billion. TESARO, Inc. has a 52-week low of $83.26 and a 52-week high of $192.94. The company has a 50 day moving average price of $125.98 and a 200 day moving average price of $147.86.
TESARO (NASDAQ:TSRO) last released its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($2.82) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($2.52) by $0.30. TESARO had a negative net margin of 1,301.19% and a negative return on equity of 104.00%. The firm had revenue of $29.50 million during the quarter, compared to analyst estimates of $18.61 million. During the same period in the prior year, the business earned ($1.28) EPS. The business’s revenue for the quarter was down 17.6% compared to the same quarter last year. On average, analysts anticipate that TESARO, Inc. will post ($8.70) earnings per share for the current fiscal year.
WARNING: “TESARO, Inc. (TSRO) Shares Bought by Pioneer Investment Management Inc.” was posted by BNB Daily and is the property of of BNB Daily. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this report can be accessed at https://www.baseball-news-blog.com/2017/08/19/pioneer-investment-management-inc-raises-stake-in-tesaro-inc-tsro-updated.html.
Several analysts have recently weighed in on the company. Jefferies Group LLC set a $124.00 price objective on TESARO and gave the company a “hold” rating in a report on Thursday. Credit Suisse Group set a $190.00 price objective on TESARO and gave the company a “buy” rating in a report on Friday. Evercore ISI started coverage on TESARO in a research report on Wednesday. They set an “in-line” rating and a $121.00 target price on the stock. Robert W. Baird reaffirmed a “neutral” rating and set a $140.00 target price (down from $155.00) on shares of TESARO in a research report on Thursday, August 10th. Finally, Morgan Stanley reaffirmed an “overweight” rating and set a $183.00 target price on shares of TESARO in a research report on Thursday, August 10th. One analyst has rated the stock with a sell rating, eleven have issued a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $173.47.
In other TESARO news, VP Edward C. English sold 8,500 shares of TESARO stock in a transaction dated Tuesday, June 6th. The stock was sold at an average price of $138.65, for a total value of $1,178,525.00. Following the sale, the vice president now owns 5,396 shares of the company’s stock, valued at approximately $748,155.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 40.50% of the company’s stock.
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
Receive News & Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related companies with MarketBeat.com's FREE daily email newsletter.